PURPOSE OF REVIEW: The new nomenclature of steatotic liver disease overcame the stigma associated with non-alcohol fatty liver disease term changing to metabolic dysfunction associated steatototic liver disease (MASLD), and introduced a new entity of metabolic dysfunction and alcohol associated liver disease or Met-ALD. Introducing MetALD as a distinct clinical entity is challenging in clinical practice, but at the same time brings in opportunities for research to understand the various aspects of risk stratification, prognosis and natural history, pharmacological management, and designing clinical trials. This article delves into all these aspects of Met-ALD.
RECENT FINDINGS: This overview provides new insights in the disease and pathogenesis of liver injury with interaction and pathways driven by both the risk factors of cardiometabolic risk factors and of alcohol use in patients with Met-ALD.
SUMMARY: MetALD is a distinct form of steatotic liver disease with phenotype overlapping both MASLD and alcohol associated liver disease (ALD). It addresses a key clinical reality thatand synergistically worsen liver injury. By filling a major gap in current classifications, MetALD promotes accurate patient stratification, improved screening for dual risk factors, and tailored therapeutic strategies. Its recognition also has significant implications for clinical trials, epidemiologic research, and public health, given the global rise in obesity and persistent alcohol use. metabolic dysfunction and alcohol consumption frequently coexist
